Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide causes diarrhoea in a significant proportion of people who take it, primarily because slowing the movement of food through your gut disrupts how the bowel handles fluid and waste. In the pivotal STEP 1 trial, published in the New England Journal of Medicine, diarrhoea was one of the most commonly reported side effects among participants taking semaglutide 2.4mg. The NHS semaglutide medicines page lists it alongside nausea, vomiting and constipation as part of the expected gastrointestinal profile of this medicine. Semaglutide is a prescription-only medicine, which means a prescriber assesses whether it is suitable for you before treatment begins — and that conversation includes a frank discussion of side effects like this one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial enrolled 1,961 adults with obesity and reported that gastrointestinal events were the most common reason for side-effect-related discontinuation, with diarrhoea affecting a substantially higher proportion of participants in the semaglutide group than those on placebo. This isn't a rare or unexpected finding: the Summary of Product Characteristics for Wegovy (semaglutide 2.4mg), available via the electronic Medicines Compendium, lists diarrhoea as a very common side effect, meaning it affects more than one in ten people taking it.
The pattern across the STEP programme is consistent: GI effects cluster in the early weeks and after each dose step-up. That isn't coincidence. It reflects how the medicine works at a physiological level.
For a broader picture of Wegovy's side-effect profile beyond the GI tract, the full Wegovy side effects page covers the complete list from the SmPC in plain language.
Semaglutide activates GLP-1 receptors found throughout the gastrointestinal tract, not just in the pancreas and brain. One of the effects of GLP-1 receptor activation is delayed gastric emptying, food leaves the stomach more slowly than usual. This is partly responsible for the reduced appetite the medicine produces, but it also changes the rhythm of the whole digestive system.
When gut motility is disrupted, the colon's ability to absorb water from stool can be affected. The result, for some people, is looser or more frequent bowel movements. Nausea and diarrhoea often appear together in the early weeks for this reason. If you want to understand why Wegovy causes diarrhoea at a physiological level, the bowel's tendency to recalibrate over time is central to that explanation, which is also why symptoms frequently ease without any change to the dose.
People sometimes find the problem is worse with fatty or heavily processed meals. Keeping a quick mental note of what you ate in the two hours before symptoms appeared (a habit that takes about thirty seconds) can help you spot patterns worth mentioning to your prescriber.
If you're curious about how often semaglutide causes diarrhoea and what affects the likelihood, that page goes further into the frequency data.
Most diarrhoea on semaglutide is self-limiting and mild-to-moderate. However, certain signs need prompt attention and should not be waited out.
Seek medical help the same day (or call 999 if severe) in any of these situations: diarrhoea that is bloody or contains mucus; diarrhoea accompanied by severe stomach pain, especially pain that radiates towards the back (this combination can be a sign of pancreatitis, which the MHRA highlighted in a Drug Safety Update issued in January 2026 as a known but infrequent serious risk with GLP-1 medicines); signs of significant dehydration such as dizziness on standing, very dark urine, or feeling faint; and diarrhoea that has not improved at all after two weeks despite staying well hydrated and eating carefully.
You can also report side effects directly to the MHRA through Yellow Card. Reporting helps regulators track real-world safety signals for medicines like semaglutide that are still under additional monitoring.
If you're concerned about fatigue alongside loose stools (possibly from dehydration) this page on Wegovy and tiredness addresses that overlap.
There is no single fix, but several approaches consistently help. Eating smaller portions and chewing slowly reduces the load on a gut that is already moving differently. Reducing very fatty food during the first weeks of each new dose tends to lessen GI disruption for many people. Prioritising plain, easy-to-digest foods (rice, plain chicken, cooked vegetables) in the days after a dose increase can make the adjustment period shorter.
Hydration is the most important practical step. Diarrhoea causes fluid and electrolyte loss faster than most people realise, and that matters more when you are also eating less than usual. Water, diluted squash and oral rehydration sachets (available over the counter) are all reasonable options if symptoms are significant. For a detailed look at whether semaglutide can give you diarrhoea and what you can do about it, including which dietary and lifestyle factors make a difference, that page covers practical management in more depth.
Do not adjust your dose timing or skip a dose without speaking to your prescriber first. If diarrhoea is severe enough that you're considering stopping treatment, that conversation should happen before you stop, not after. Our prescribers discuss exactly these situations as part of every consultation, including how to handle side effects that arise during treatment. If you're exploring what treatment involves, starting a free consultation is the first step. For broader context on the medicine itself, the Wegovy overview page covers how it works and who it's licensed for in the UK.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.